How Tokenization can Transform Pharma Licensing and Royalty Financing The pharmaceutical and biotech industries face a critical financing paradox: groundbreaking medical innovations require massive capital investment, yet traditional funding mechanisms create significant barriers to accessing the capital needed to bring life-saving treatments to market.
Royalty financing and synthetic royalties are reshaping biotech and pharma funding in Europe. As venture funding tightens—Q2 2025 saw biotech venture capital drop to $4.8B, falling to pre-2018 levels—European companies are increasingly adopting alternative funding models. Notably, over 20% of global synthetic royalty and drug development deals now involve European players, a major leap in just two years.
Imdelltra is a first-in-class immunotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC) marketed by Amgen
Royalty Pharma to pay $885 million upfront; BeOne Medicines to retain a $65 million option to sell additional portion of its royalty
